Pacific Biosciences of California (PACB) : Oracle Investment Management Inc scooped up 1,816,297 additional shares in Pacific Biosciences of California during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 4,998,566 shares of Pacific Biosciences of California which is valued at $41,288,155.Pacific Biosciences of California makes up approximately 6.07% of Oracle Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Geode Capital Management boosted its stake in PACB in the latest quarter, The investment management firm added 87,690 additional shares and now holds a total of 574,957 shares of Pacific Biosciences of California which is valued at $4,473,165.Blackrock Fund Advisors boosted its stake in PACB in the latest quarter, The investment management firm added 345,672 additional shares and now holds a total of 3,449,000 shares of Pacific Biosciences of California which is valued at $25,143,210. Pacific Biosciences of California makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Blackrock Advisors reduced its stake in PACB by selling 1,314 shares or 0.08% in the most recent quarter. The Hedge Fund company now holds 1,684,020 shares of PACB which is valued at $12,276,506. Pacific Biosciences of California makes up approx 0.01% of Blackrock Advisors’s portfolio.Ifp Advisors Inc reduced its stake in PACB by selling 850 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 118,447 shares of PACB which is valued at $816,100. Pacific Biosciences of California makes up approx 0.05% of Ifp Advisors Inc’s portfolio.
Pacific Biosciences of California closed down -0.04 points or -0.52% at $7.61 with 10,19,204 shares getting traded on Monday. Post opening the session at $7.69, the shares hit an intraday low of $7.54 and an intraday high of $7.75 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Pacific Biosciences of California reported $-0.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Nov 2, 2016. Analyst had a consensus of $-0.20. The company had revenue of $25.10 million for the quarter, compared to analysts expectations of $24.70 million. The company’s revenue was up 80.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.02 EPS.
Many Wall Street Analysts have commented on Pacific Biosciences of California. Shares were Reiterated by Cantor Fitzgerald on Nov 3, 2016 to “Buy” and Lowered the Price Target to $ 15 from a previous price target of $18 .
Pacific Biosciences of California Inc. designs develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Company’s Single Molecule Real-Time (SMRT) technology its products enable de novo genome assembly to finish genomes in order to more fully identify annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule real-time detection of biological processes. Based on its SMRT technology the Company introduced the PacBio RS II System to address many of the limitations.